T20 Yellow Pill.

In healthy male elderly subjects (65 years or over) after a 10 mg dose, a lower oral clearance of tadalafil, resulting in 25% higher exposure (AUC) with no effect on C maxwas observed relative to that in healthy subjects 19 to 45 years of age. In clinical pharmacology studies using single-dose tadalafil (5 to 10 mg), tadalafil exposure (AUC) doubled in subjects with mild (creatinine clearance 51 to 80 mL/min) or moderate (creatinine clearance 31 to 50 mL/min) renal impairment. Hemodialysis (performed between 24 and 30 hours post-dose) contributed negligibly to tadalafil or metabolite elimination [see Dosage and Administration ( 2.2)] . Insufficient data are available for subjects with severe hepatic impairment (Child-Pugh Class C) [see Dosage and Administration ( 2.3)] . In male patients with diabetes mellitus after a 10 mg tadalafil dose, exposure (AUC) was reduced approximately 19% and Cmaxwas 5% lower than that observed in healthy subjects. Pharmacokinetic studies have included subjects from different ethnic groups, and no differences in the typical exposure to tadalafil have been identified.

Comparing Which Lasts Longer

Ritonavir increased tadalafil 20–mg single-dose exposure relative to the values for tadalafil alone. Although specific interactions have not been studied, other HIV protease inhibitors would likely increase tadalafil exposure. Rifampin (600 mg daily), a CYP3A inducer, reduced tadalafil 10 mg single–dose exposure (AUC) by 88% and Cmax by 46%, relative to the values for tadalafil 10 mg alone [see Drug Interactions (7.5)] . Bosentan, a substrate of CYP2C9 and CYP3A and a moderate inducer of CYP3A, CYP2C9 and possibly CYP2C19, reduced tadalafil systemic exposure following multiple-dose co-administration (Figure 2). Although specific interactions have not been studied, other CYP3A inducers, such as carbamazepine, phenytoin, and phenobarbital, would likely decrease tadalafil exposure.

Tadalafil may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

Exposure changes of tadalafil following co-administration with other drugs are shown in Figure 2. b[see Dosage and Administration (2.4)]. Figure 2: Impact of Other Drugs on the Pharmacokinetics of Tadalafil Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 (CYP) isoforms. Exposure changes of drugs following co-administration with tadalafil are shown in Figure 3. aA small augmentation (increase of 3 beats per minute) in heart rate was observed with theophylline. In healthy female and male subjects following single and multiple-doses of tadalafil, no clinically relevant differences in exposure (AUC and C max) were observed. Tadalafil is a substrate of and predominantly metabolized by CYP3A. Ketoconazole increased tadalafil exposure relative to the values for tadalafil alone (Figure 2). Although specific interactions have not been studied, other CYP3A inhibitors, such as erythromycin, itraconazole, and grapefruit juice, would likely increase tadalafil exposure.

Product	Dosage	Quantity + Bonus	Price
Cialis Professional	20mg	60 + 2 Pills	183.83€ 175.08€	Buy
Cialis Generic	5mg	10 Pills	29.39€ 27.99€	Buy
Cialis Soft Tabs	20mg	270 + 10 Pills	471.40€ 448.95€	Buy
Cialis Generic	2.5mg	10 Pills	28.51€ 27.15€	Buy
Cialis Professional	40mg	180 + 4 Pills	618.23€ 588.79€	Buy
Cialis Original	20mg	120 + 8 Pills	497.29€ 473.61€	Buy
Cialis Generic	5mg	360 + 10 Pills	268.08€ 255.31€	Buy
Cialis Professional	20mg	10 Pills	48.29€ 45.99€	Buy
Cialis Professional	40mg	10 Pills	65.09€ 61.99€	Buy
Cialis Generic	20mg	120 + 8 Pills	188.15€ 179.19€	Buy
Cialis Professional	20mg	20 Pills	78.33€ 74.60€	Buy
Cialis Generic	20mg	180 + 10 Pills	254.09€ 241.99€	Buy
Cialis Original	20mg	48 + 4 Pills	224.69€ 213.99€	Buy

Ritonavir increased tadalafil 20–mg single-dose exposure relative to the values for tadalafil alone.

7.1 Nitrates

Although specific interactions have not been studied, other HIV protease inhibitors would likely increase tadalafil exposure. Rifampin (600 mg daily), a CYP3A inducer, reduced tadalafil 10 mg single–dose exposure (AUC) by 88% and Cmax by 46%, relative to the values for tadalafil 10 mg alone [see Drug Interactions (7.5)] .

What are the differences between brand-name and generic Cialis?

bTadalafil (40 mg qd) had no clinically significant effect on exposure (AUC and C max) of bosentan metabolites. Figure 3: Impact of Tadalafil on the Pharmacokinetics of Other Drugs 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of FertilityCarcinogenesis— Tadalafil was not carcinogenic to rats or mice when administered daily for 2 years at doses up to 400 mg/kg/day. Systemic drug exposures, as measured by AUC of unbound tadalafil, were approximately 5–fold for mice, and 7– and 14–fold for male and female rats, respectively, the exposures at the maximum recommended human dose (MRHD) of 40 mg.Mutagenesis— Tadalafil was not mutagenic in the in vitrobacterial Ames assays or the forward mutation test in mouse lymphoma cells. Tadalafil was not clastogenic in the in vitro chromosomal aberration test in human lymphocytes or the in vivo rat micronucleus assays.Impairment of Fertility— There were no effects on fertility, reproductive performance or reproductive organ morphology in male or female rats given oral doses of tadalafil up to 400 mg/kg/day, a dose producing AUCs for unbound tadalafil of 6–fold for males or 17–fold for females the exposures at the MRHD of 40 mg. In beagle dogs given tadalafil daily for 3 to 12 months, there was treatment–related non–reversible degeneration and atrophy lilly cialis of the seminiferous tubular epithelium in the testes in 20 to 100% of the dogs that resulted in a decrease in spermatogenesis in 40 to 75% of the dogs at doses of ≥10 mg/kg/day.

How Does Cialis Work?

Systemic exposure (based on AUC) at no–observed–adverse-effect–level (NOAEL) (10 mg/kg/day) for unbound tadalafil was similar to that expected in humans at the MRHD of 40 mg.There were no treatment–related testicular findings in rats or mice treated with doses up to 400 mg/kg/day for 2 years.13.2 Animal Toxicology and/or PharmacologyAnimal studies showed vascular inflammation in tadalafil–treated mice, rats, and dogs. In mice and rats, lymphoid necrosis and hemorrhage were seen in the spleen, thymus, and mesenteric lymph nodes at unbound tadalafil exposure of 1– to 17–fold the human exposure (AUCs) at the MRHD of 40 mg. In dogs, an increased incidence of disseminated arteritis was observed in 1– and 6-month studies at unbound tadalafil exposure of 0.5– to 38–fold the human exposure (AUC) at the MRHD of 40 mg. In a 12–month dog study, no disseminated arteritis was observed, but 2 dogs exhibited marked decreases in white blood cells (neutrophils) and moderate decreases in platelets with inflammatory signs at unbound tadalafil exposures of approximately 4– to 10–fold the human exposure at the MRHD of 40 mg. The abnormal blood–cell findings were reversible within 2 weeks upon removal of the drug. Bosentan, a substrate of CYP2C9 and CYP3A and a moderate inducer of CYP3A, CYP2C9 and possibly CYP2C19, reduced tadalafil systemic exposure following multiple-dose co-administration (Figure 2). Although specific interactions have not been studied, other CYP3A inducers, such as carbamazepine, phenytoin, and phenobarbital, would likely decrease tadalafil exposure. Exposure changes of tadalafil following co-administration with other drugs are shown in Figure 2.

Brand names

Carcinogenesis— Tadalafil was not carcinogenic to rats or mice when administered daily for 2 years at doses up to 400 mg/kg/day. Systemic drug exposures, as measured by AUC of unbound tadalafil, were approximately 5–fold for mice, and 7– and 14–fold for male and female rats, respectively, the exposures at the maximum recommended human dose (MRHD) of 40 mg. Mutagenesis— Tadalafil was not mutagenic in the in vitrobacterial Ames assays or the forward mutation test in mouse lymphoma cells. Impairment of Fertility— There were no effects on fertility, reproductive performance or reproductive organ morphology in male or female rats given oral doses of tadalafil up to 400 mg/kg/day, a dose producing AUCs for unbound tadalafil of 6–fold for males or 17–fold for females the exposures at the MRHD of 40 mg. Systemic exposure (based on AUC) at no–observed–adverse-effect–level (NOAEL) (10 mg/kg/day) for unbound tadalafil was similar to that expected in humans at the MRHD of 40 mg.

Understanding PAH and BPH

There were no treatment–related testicular findings in rats or mice treated with doses up to 400 mg/kg/day for 2 years. Animal studies showed vascular inflammation in tadalafil–treated mice, rats, and dogs. 14 CLINICAL STUDIES 14.1 Tadalafil tablets for Pulmonary Arterial HypertensionA randomized, double-blind, 16 week placebo-controlled study was conducted in 405 patients with pulmonary arterial hypertension, defined as a resting mean pulmonary artery pressure (mPAP) ≥25 mm Hg, pulmonary capillary wedge pressure (PCWP) ≤15 mm Hg, and pulmonary vascular resistance (PVR) ≥3 Wood units via right heart catheterization. Allowed background therapy included bosentan (maintenance dosing up to 125 mg twice daily) and chronic anticoagulation. The use of prostacyclin or analogue, L–arginine, phosphodiesterase inhibitor, or other chronic PAH medications were not permitted.Subjects were randomly assigned to 1 of 5 treatment groups (tadalafil 2.5, 10, 20, 40 mg, or placebo) in a 1:1:1:1:1 ratio. b[see Dosage and Administration (2.4)].

• Yellow Cialis pills are often taken 30 minutes prior to intimacy for best results.
• Regular use of yellow Cialis can improve erectile function over time.
• The yellow pill's profile includes a 36-hour window of effectiveness.
• Cialis (yellow pill) may cause minor side effects in some users.
• Safe use of yellow Cialis requires a medical consultation.
• Some yellow Cialis pills are designed for daily low-dose use.
• The yellow Cialis pill's vibrant color helps prevent mix-ups with other pills.
• Cialis’s proprietary formula is designed for sustained blood flow support.
• The yellow color is part of Cialis’s branding and quality assurance.
• Yellow Cialis is not suitable for everyone and requires medical screening.
• Proper storage of yellow Cialis maintains its efficacy and safety.
• Use yellow Cialis responsibly, following prescribed doses and instructions.

Figure 2: Impact of Other Drugs on the Pharmacokinetics of Tadalafil Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 (CYP) isoforms. Exposure changes of drugs following co-administration with tadalafil are shown in Figure 3. aA small augmentation (increase of 3 beats per minute) in heart rate was observed with theophylline. bTadalafil (40 mg qd) had no clinically significant effect on exposure (AUC and C max) of bosentan metabolites.

Further information

Subjects had to be at least 12 years of age and had a diagnosis of PAH that was idiopathic, heritable, related to connective tissue disease, anorexigen use, human immunodeficiency virus (HIV) infection, associated with an atrial-septal defect, or associated with surgical repair of a congenital systemic-to-pulmonary shunt of least 1 year in duration (for example, ventricular septal defect, patent ductus arteriosus). Patients with a history of left-sided heart disease, severe renal insufficiency, or pulmonary hypertension related to conditions other than specified in the inclusion criteria were not eligible for enrollment.The mean age of all subjects was 54 years (range 14 to 90 years) with the majority of subjects being Caucasian (81%) and female (78%). PAH etiologies were predominantly idiopathic or heritable PAH (61%) and related to connective tissue disease (23%). More than half (53%) of the subjects in the study were receiving concomitant bosentan therapy. The majority of subjects had a World Health Organization (WHO) Functional Class III (65%) or II (32%).

Effective treatments, trusted by over 500,000 men

The mean baseline 6-minute walk distance (6-MWD) was 343 meters. Of the 405 subjects, 341 completed the study.The primary efficacy endpoint was the change from baseline at week 16 in 6-MWD (see Figure 4). In the tadalafil tablets 40 mg treatment group, the placebo-adjusted mean change increase in 6-MWD was 33 meters (95% C.I. The improvement in 6-MWD was apparent at 8 weeks of treatment and then maintained at week 12 and week 16.Figure 4: 6-Minute Walk Distance (meters) Mean Change from Baseline, with 95% Confidence IntervalsPlacebo-adjusted changes in 6-MWD at 16 weeks were evaluated in subgroups ( seeFigure 5). In patients taking only tadalafil tablets 40 mg (i.e., without concomitant bosentan), the placebo-adjusted mean change in 6-MWD was 44 meters. Figure 3: Impact of Tadalafil on the Pharmacokinetics of Other Drugs 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of FertilityCarcinogenesis— Tadalafil was not carcinogenic to rats or mice when administered daily for 2 years at doses up to 400 mg/kg/day. Systemic drug exposures, as measured by AUC of unbound tadalafil, were approximately 5–fold for mice, and 7– and 14–fold for male and female rats, respectively, the exposures at the maximum recommended human dose (MRHD) of 40 mg.Mutagenesis— Tadalafil was not mutagenic in the in vitrobacterial Ames assays or the forward mutation test in mouse lymphoma cells.

Ingredient	Amount per Dose	Purpose	Notes
Tadalafil	20 mg	Active ingredient, vasodilator	Main component for ED
Microcrystalline Cellulose	-	Filler	Binds ingredients
Magnesium Stearate	-	Excipient	Improves pill stability
Titanium Dioxide	-	Coloring agent	Provides yellow color

Tadalafil was not clastogenic in the in vitro chromosomal aberration test in human lymphocytes or the in vivo rat micronucleus assays.Impairment of Fertility— There were no effects on fertility, reproductive performance or reproductive organ morphology in male or female rats given oral doses of tadalafil up to 400 mg/kg/day, a dose producing AUCs for unbound tadalafil of 6–fold for males or 17–fold for females the exposures at the MRHD of 40 mg. In beagle dogs given tadalafil daily for 3 to 12 months, there was treatment–related non–reversible degeneration and atrophy lilly cialis of the seminiferous tubular epithelium in the testes in 20 to 100% of the dogs that resulted in a decrease in spermatogenesis in 40 to 75% of the dogs at doses of ≥10 mg/kg/day. Systemic exposure (based on AUC) at no–observed–adverse-effect–level (NOAEL) (10 mg/kg/day) for unbound tadalafil was similar to that expected in humans at the MRHD of 40 mg.There were no treatment–related testicular findings in rats or mice treated with doses up to 400 mg/kg/day for 2 years.13.2 Animal Toxicology and/or PharmacologyAnimal studies showed vascular inflammation in tadalafil–treated mice, rats, and dogs.

How long does Cialis last?

In patients taking tadalafil tablets 40 mg and concomitant bosentan therapy, the placebo adjusted mean change in 6-MWD was 23 meters.Repaired S-P Shunts=Repaired Congenital systemic-to-pulmonary shunt.Figure 5: Placebo-adjusted Mean Change in 6-Minute Walk Distance (meters) of Tadalafil Tablets 40 mg, with 95% Confidence IntervalsThere was less clinical worsening (defined as death, lung transplantation, atrial septostomy, hospitalization because of worsening PAH, initiation of new PAH therapy [prostacyclin or analog, endothelin receptor antagonist, PDE5 inhibitor], or worsening WHO functional class) in the tadalafil tablets 40 mg group compared to the placebo group and the groups that used lower doses of tadalafil tablets.The Kaplan-Meier plot of times to clinical worsening is shown below in Figure 6.Figure 6: Kaplan-Meier Plot of Time to Clinical Worsening14.2 Long-Term Treatment of Pulmonary Arterial HypertensionPatients (N=357) from the placebo-controlled study entered a long-term extension study.

Common mild side effects

In mice and rats, lymphoid necrosis and hemorrhage were seen in the spleen, thymus, and mesenteric lymph nodes at unbound tadalafil exposure of 1– to 17–fold the human exposure (AUCs) at the MRHD of 40 mg. In dogs, an increased incidence of disseminated arteritis was observed in 1– and 6-month studies at unbound tadalafil exposure of 0.5– to 38–fold the human exposure (AUC) at the MRHD of 40 mg.

5.2 Potential for Drug Interactions When Taking Tadalafil Tablet for Once Daily Use

In healthy male elderly subjects (65 years or over) after a 10 mg dose, a lower oral clearance of tadalafil, resulting in 25% higher exposure (AUC) with no effect on C maxwas observed relative to that in healthy subjects 19 to 45 years of age. In clinical pharmacology studies using single-dose tadalafil (5 to 10 mg), tadalafil exposure (AUC) doubled in subjects with mild (creatinine clearance 51 to 80 mL/min) or moderate (creatinine clearance 31 to 50 mL/min) renal impairment. Hemodialysis (performed between 24 and 30 hours post-dose) contributed negligibly to tadalafil or metabolite elimination [see Dosage and Administration ( 2.2)] . Insufficient data are available for subjects with severe hepatic impairment (Child-Pugh Class C) [see Dosage and Administration ( 2.3)] . In male patients with diabetes mellitus after a 10 mg tadalafil dose, exposure (AUC) was reduced approximately 19% and Cmaxwas 5% lower than that observed in healthy subjects.

Are they approved by the FDA (Food and Drug Administration)?

Pharmacokinetic studies have included subjects from different ethnic groups, and no differences in the typical exposure to tadalafil have been identified. In healthy female and male subjects following single and multiple-doses of tadalafil, no clinically relevant differences in exposure (AUC and C max) were observed. Tadalafil is a substrate of and predominantly metabolized by CYP3A. Ketoconazole increased tadalafil exposure relative to the values for tadalafil alone (Figure 2). Although specific interactions have not been studied, other CYP3A inhibitors, such as erythromycin, itraconazole, and grapefruit juice, would likely increase tadalafil exposure. In a 12–month dog study, no disseminated arteritis was observed, but 2 dogs exhibited marked decreases in white blood cells (neutrophils) and moderate decreases in platelets with inflammatory signs at unbound tadalafil exposures of approximately 4– to 10–fold the human exposure at the MRHD of 40 mg. The abnormal blood–cell findings were reversible within 2 weeks upon removal of the drug. Carcinogenesis— Tadalafil was not carcinogenic to rats or mice when administered daily for 2 years at doses up to 400 mg/kg/day. Systemic drug exposures, as measured by AUC of unbound tadalafil, were approximately 5–fold for mice, and 7– and 14–fold for male and female rats, respectively, the exposures at the maximum recommended human dose (MRHD) of 40 mg. Mutagenesis— Tadalafil was not mutagenic in the in vitrobacterial Ames assays or the forward mutation test in mouse lymphoma cells. Impairment of Fertility— There were no effects on fertility, reproductive performance or reproductive organ morphology in male or female rats given oral doses of tadalafil up to 400 mg/kg/day, a dose producing AUCs for unbound tadalafil of 6–fold for males or 17–fold for females the exposures at the MRHD of 40 mg. Systemic exposure (based on AUC) at no–observed–adverse-effect–level (NOAEL) (10 mg/kg/day) for unbound tadalafil was similar to that expected in humans at the MRHD of 40 mg. There were no treatment–related testicular findings in rats or mice treated with doses up to 400 mg/kg/day for 2 years. Animal studies showed vascular inflammation in tadalafil–treated mice, rats, and dogs.

• Physical features of yellow Cialis include smooth coating and visible markings.
• Patients should avoid alcohol and grapefruit products while taking yellow Cialis.
• The yellow color of Cialis pills signifies it's a PDE5 inhibitor.
• The yellow Cialis pill is designed for quick absorption in the bloodstream.
• Before use, check the packaging for authenticity of the yellow Cialis.
• Side effects like dizziness may occur after taking yellow Cialis.
• The yellow Cialis pill is known for its consistency in quality.
• Cialis's active ingredient, tadalafil, is responsible for its effects.
• Always follow dosing guidelines to prevent potential health risks.
• The yellow Cialis pill enhances sexual performance by improving blood flow.
• Education about yellow Cialis helps patients use it effectively.
• Medical consultation is essential when considering yellow Cialis treatment.

14 CLINICAL STUDIES 14.1 Tadalafil tablets for Pulmonary Arterial HypertensionA randomized, double-blind, 16 week placebo-controlled study was conducted in 405 patients with pulmonary arterial hypertension, defined as a resting mean pulmonary artery pressure (mPAP) ≥25 mm Hg, pulmonary capillary wedge pressure (PCWP) ≤15 mm Hg, and pulmonary vascular resistance (PVR) ≥3 Wood units via right heart catheterization. Allowed background therapy included bosentan (maintenance dosing up to 125 mg twice daily) and chronic anticoagulation. The use of prostacyclin or analogue, L–arginine, phosphodiesterase inhibitor, or other chronic PAH medications were not permitted.Subjects were randomly assigned to 1 of 5 treatment groups (tadalafil 2.5, 10, 20, 40 mg, or placebo) in a 1:1:1:1:1 ratio. Subjects had to be at least 12 years of age and had a diagnosis of PAH that was idiopathic, heritable, related to connective tissue disease, anorexigen use, human immunodeficiency virus (HIV) infection, associated with an atrial-septal defect, or associated with surgical repair of a congenital systemic-to-pulmonary shunt of least 1 year in duration (for example, ventricular septal defect, patent ductus arteriosus). Patients with a history of left-sided heart disease, severe renal insufficiency, or pulmonary hypertension related to conditions other than specified in the inclusion criteria were not eligible for enrollment.The mean age of all subjects was 54 years (range 14 to 90 years) with the majority of subjects being Caucasian (81%) and female (78%). PAH etiologies were predominantly idiopathic or heritable PAH (61%) and related to connective tissue disease (23%). More than half (53%) of the subjects in the study were receiving concomitant bosentan therapy. The majority of subjects had a World Health Organization (WHO) Functional Class III (65%) or II (32%). The mean baseline 6-minute walk distance (6-MWD) was 343 meters. Of the 405 subjects, 341 completed the study.The primary efficacy endpoint was the change from baseline at week 16 in 6-MWD (see Figure 4). In the tadalafil tablets 40 mg treatment group, the placebo-adjusted mean change increase in 6-MWD was 33 meters (95% C.I. The improvement in 6-MWD was apparent at 8 weeks of treatment and then maintained at week 12 and week 16.Figure 4: 6-Minute Walk Distance (meters) Mean Change from Baseline, with 95% Confidence IntervalsPlacebo-adjusted changes in 6-MWD at 16 weeks were evaluated in subgroups ( seeFigure 5). In patients taking only tadalafil tablets 40 mg (i.e., without concomitant bosentan), the placebo-adjusted mean change in 6-MWD was 44 meters. In patients taking tadalafil tablets 40 mg and concomitant bosentan therapy, the placebo adjusted mean change in 6-MWD was 23 meters.Repaired S-P Shunts=Repaired Congenital systemic-to-pulmonary shunt.Figure 5: Placebo-adjusted Mean Change in 6-Minute Walk Distance (meters) of Tadalafil Tablets 40 mg, with 95% Confidence IntervalsThere was less clinical worsening (defined as death, lung transplantation, atrial septostomy, hospitalization because of worsening PAH, initiation of new PAH therapy [prostacyclin or analog, endothelin receptor antagonist, PDE5 inhibitor], or worsening WHO functional class) in the tadalafil tablets 40 mg group compared to the placebo group and the groups that used lower doses of tadalafil tablets.The Kaplan-Meier plot of times to clinical worsening is shown below in Figure 6.Figure 6: Kaplan-Meier Plot of Time to Clinical Worsening14.2 Long-Term Treatment of Pulmonary Arterial HypertensionPatients (N=357) from the placebo-controlled study entered a long-term extension study.